Mabion (LTS:0QGW) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QGW Mabion SA LTS:0QGW
31 GF Score
Price zł37.60
GF Value zł10.56
! 4 Warning Signs
View Full Analysis

What is Mabion Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0QGW
31GF Score
Mabion SA LTS:0QGW
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (LTS:0QGW) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł37.60 is trading 256.1% above its estimated GF Value™ of zł10.56.

Key valuation signals for LTS:0QGW:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: zł10.56 vs. price of zł37.60 (256.1% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QGW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges MAB:Poland272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
31GF Score

Get the complete analysis for LTS:0QGW

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł37.60
Price
zł10.56
GF Value